Opinion|Videos|February 1, 2024
Patient-Centric Care in R/R MM
Author(s)Ursula Linne-Mclaren, RN
Nurse Linne-Mclaren provides her insights into the proactive measures, monitoring strategies, and experiences related to talquetamab-associated adverse events, along with a broader perspective on prophylactic measures for managing potential adverse events in bispecific therapies.
Advertisement
Episodes in this series
Advertisement
Related to this article
In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
Advertisement
Advertisement
Trending on CancerNetwork
1
Pasritamig Plus JNJ-9401 Yields 73% PSA Response in Metastatic CRPC
2
Nogapendekin Alfa/BCG Earns Israeli Approval in BCG-Unresponsive NMIBC
3
Cesalatamig Monotherapy Yields Responses in PD-(L)1–Resistant NSCLC
4
PIKTOR Plus Paclitaxel Yields Responses in Pretreated PAM-Mutated Endometrial Cancer
5